Biogen Raises Guidance as It Looks to the Pipeline for Growth

Biogen (NASDAQ: BIIB) put up relatively impressive sales numbers in the second quarter, with earnings per share growing like gangbusters as the drugmaker cut expenses and repurchased shares to boost the bottom line.

Metric

Q2 2019

Continue reading

Quelle Fool.com